<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-23157" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Unconjugated Hyperbilirubinemia</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Singh</surname>
            <given-names>Anand</given-names>
          </name>
          <aff>National Cancer Institute, NIH</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Koritala</surname>
            <given-names>Thoyaja</given-names>
          </name>
          <aff>Mayo Clinic</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jialal</surname>
            <given-names>Ishwarlal</given-names>
          </name>
          <aff>VA MEDICAL CENTER, MATHER , CA</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anand Singh declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Thoyaja Koritala declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ishwarlal Jialal declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>20</day>
          <month>2</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-23157.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Unconjugated hyperbilirubinemia is a condition defined as elevated serum or plasma bilirubin (unconjugated) levels above the reference range of the laboratory. Unconjugated hyperbilirubinemia usually results from dysregulation in the bilirubin metabolism that includes increased production, impaired hepatic uptake, and decreased conjugation of bilirubin. In newborns, unconjugated hyperbilirubinemia is very common, and increased bilirubin (unconjugated) levels can cause life-threatening kernicterus. This activity describes the pathophysiology and management of unconjugated hyperbilirubinemia. It also highlights the importance of teamwork in the management of patients with this disease.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the physiology of bilirubin metabolism.</p></list-item><list-item><p>Explain how to differentiate unconjugated hyperbilirubinemia from conjugated hyperbilirubinemia.</p></list-item><list-item><p>Identify the several causes of unconjugated hyperbilirubinemia and summarize the available treatment options.</p></list-item><list-item><p>Summarize the importance of improving care coordination among interprofessional team members to improve outcomes for patients affected by unconjugated hyperbilirubinemia.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23157&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23157">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-23157.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Hyperbilirubinemia is a condition defined as elevated serum or plasma bilirubin levels above the reference range of the laboratory, and it is due to disorders of bilirubin metabolism. Depending on the form of bilirubin present in serum, hyperbilirubinemia can be further classified as unconjugated (indirect) or conjugated (direct). Unconjugated hyperbilirubinemia (albumin-bound) usually results from increased production, impaired hepatic uptake, and decreased conjugation of bilirubin.<xref ref-type="bibr" rid="article-23157.r1">[1]</xref><xref ref-type="bibr" rid="article-23157.r2">[2]</xref>&#x000a0;In neonates, jaundice typically occurs due to unconjugated hyperbilirubinemia, which is characterized by the increased levels of indirect or unconjugated bilirubin (UCB) in the serum. In newborns, the increased concentration of UCB can cross the blood-brain barrier, and deposit in the basal ganglia or cerebellum causing a bilirubin-induced encephalopathy or kernicterus<xref ref-type="bibr" rid="article-23157.r3">[3]</xref>. Several inherited disorders can also produce unconjugated hyperbilirubinemia, including Gilbert syndrome, Crigler-Najjar syndromes type I and II, and inherited disorders causing hemolytic anemia.<xref ref-type="bibr" rid="article-23157.r4">[4]</xref><xref ref-type="bibr" rid="article-23157.r5">[5]</xref></p>
      </sec>
      <sec id="article-23157.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Bilirubin, a yellow-orange bile pigment, is the catabolic product of heme metabolism. Approximately 85 percent of the heme moiety comes from the hemoglobin degradation of red blood cells, while the remaining derives from the ineffective erythropoiesis and the breakdown of other hemoproteins such as cytochromes, myoglobin, and catalase.<xref ref-type="bibr" rid="article-23157.r6">[6]</xref>&#x000a0;The conversion of heme to bilirubin is a two-step reaction, in the first step the microsomal heme oxy&#x000ad;genase enzyme of the reticuloendothelial system, converts heme to biliverdin, which in turn is reduced to unconjugated bilirubin (UCB) by a second enzyme biliverdin reductase.<xref ref-type="bibr" rid="article-23157.r7">[7]</xref>&#x000a0;The UCB is lipophilic. UCB tightly bound to albumin is trans&#x000ad;ported to the liver. &#x000a0;The entry of UCB into the liver has not been elucidated, and the best candidate appears to be a bilirubin transporter. In liver hepatocytes, UCB dissociates from albumin and binds to proteins of the glutathione-S-transferases family that present it for conjugation and prevent it from effluxing from the liver. Next, unconjugated bilirubin gets conjugated with one or two molecules of glucuronic acid by the enzyme uridine diphospho-glucuronate glucuronosyltransferase (UGT1A1), which forms bilirubin monoglucuronide and bilirubin diglucuronide respectively.<xref ref-type="bibr" rid="article-23157.r7">[7]</xref><xref ref-type="bibr" rid="article-23157.r8">[8]</xref>&#x000a0;Conjugation increases the solubility of bilirubin in plasma and thereby enhances its elimina&#x000ad;tion from the body. The conjugated bilirubin (CB) is then pumped into bile via an energy-requiring process requiring the multidrug resistance-associated protein 2 (MRP2).<xref ref-type="bibr" rid="article-23157.r9">[9]</xref> This process also reduces the ability of bilirubin to diffuse across the blood-brain barrier. Therefore, unconjugated hyperbilirubinemia can result from dysfunction of any of these conjugation steps. In neonates, inefficient conjugation of bilirubin leads to unconjugated hyperbiliru&#x000ad;binemia (physiologic neonatal jaundice). See <bold>Figure.</bold>&#x000a0;Metabolic Pathway for Bilirubin in the Hepatocyte.&#x000a0;</p>
        <p>Unconjugated hyperbilirubinemia arises in one of the three major pathophysiologic conditions or a combination of them:</p>
        <list list-type="bullet">
          <list-item>
            <p>Increased bilirubin production</p>
          </list-item>
          <list-item>
            <p>Impaired bilirubin uptake</p>
          </list-item>
          <list-item>
            <p>Impaired bilirubin conjugation</p>
          </list-item>
        </list>
        <p>Increased bilirubin production and consequential unconjugated hyperbilirubi&#x000ad;nemia can result from increased catabolic degradation of hemoglobin and other heme proteins, typically due to accelerated hemolysis, a large hematoma, dyserythropoiesis (e.g., megaloblastic and sideroblastic anemias), or sometimes due to destruction of transfused erythrocytes. In these conditions, patients with normal liver function efficiently conjugate and excrete the excess bilirubin.<xref ref-type="bibr" rid="article-23157.r2">[2]</xref><xref ref-type="bibr" rid="article-23157.r10">[10]</xref>&#x000a0;As a result, the serum levels of unconjugated bilirubin remain modest (1&#x000a0;to 4 mg/dL) and rarely exceed 4&#x000a0;mg/dL. Prolonged hemolysis can lead to severe unconjugated hyperbilirubinemia in patients with concurrent hepatic dysfunction.</p>
        <p>The impaired hepatic uptake of bilirubin can be the result of decreased bilirubin delivery to the liver and inefficient uptake of bilirubin by hepatocytes, usually resulting from reduced hepatic blood flow (congestive heart failure and portosystemic shunts) and drugs/contrast administration. The unconjugated hyperbilirubinemia induced by several drugs (rifampin, flavaspidic acid, novobiocin, and various chole&#x000ad;cystographic contrast agents), generally resolves within 48 hours of drug discontinuation.<xref ref-type="bibr" rid="article-23157.r11">[11]</xref></p>
        <p>Impaired bilirubin conjugation&#x000a0;can result from hereditary defects, including Gilbert syndrome and the Crigler-Najjar syndrome type I and II, that cause a decrease or loss of UDP-glucuronosyltransferase (UGT1A1) activity, an enzyme responsible for conjugation of bilirubin with glucuronic acid.<xref ref-type="bibr" rid="article-23157.r4">[4]</xref>&#x000a0;Lucy-Driscoll syndrome, also known as maternal serum jaundice, a form of transient familial neonatal unconjugated hyperbilirubinemia, is a rare metabolic disorder caused by a UGT1A1 inhibitor usually present in the maternal serum.<xref ref-type="bibr" rid="article-23157.r12">[12]</xref>&#x000a0;Most newborns develop unconjugated hyperbilirubinemia (neonatal jaundice) because of hepatic immaturity and low activity of UGT1A1 during days 2 to 5. Breast milk feeding increases bilirubin levels in infants which results in maternal milk jaundice.<xref ref-type="bibr" rid="article-23157.r13">[13]</xref><xref ref-type="bibr" rid="article-23157.r14">[14]</xref>&#x000a0;Lactation failure also results in hyperbilirubinemia due to insufficient caloric intake, which results in decreased bilirubin clearance, and increased enterohepatic circulation.<xref ref-type="bibr" rid="article-23157.r15">[15]</xref>&#x000a0;Drugs such as novobiocin,&#x000a0;pregnanediol, chloramphenicol, gentamycin, and several HIV protease inhibitors can induce&#x000a0;hyperbilirubinemia&#x000a0;by inhibiting the UGT1A1 enzyme.<xref ref-type="bibr" rid="article-23157.r16">[16]</xref>&#x000a0;In newborns, ABO/Rh incompatibility may lead to hyperbilirubinemia and consequently, neonatal jaundice.<xref ref-type="bibr" rid="article-23157.r10">[10]</xref></p>
      </sec>
      <sec id="article-23157.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Approximately 50% of full-term and 80% of preterm infants develop jaundice in the first 2&#x000a0;to 4 days after birth when serum bilirubin levels are greater than or equal to 5mg/dL.<xref ref-type="bibr" rid="article-23157.r17">[17]</xref>&#x000a0;Crigler-Najjar syndrome is a very rare disease with less than fifty cases in the United States and approximately 1 case per million births worldwide.<xref ref-type="bibr" rid="article-23157.r18">[18]</xref> In the United States, the prevalence of Gilbert syndrome is relatively higher; around 9% of the population is homozygous for UGT1A1 mutation. In Gilbert syndrome, ethnic groups' specific mutations occur at a different site of the UGT1A1 gene.<xref ref-type="bibr" rid="article-23157.r19">[19]</xref> For example, Gilbert syndrome in the white population is commonly associated with the mutation in the TATAA element of the UGT1A1 promoter region.<xref ref-type="bibr" rid="article-23157.r20">[20]</xref>&#x000a0;Neonatal jaundice is common in male infants, while Crigler-Najjar syndrome does not correlate with sex. At the stage of puberty, Gilbert syndrome is more common in males than females, which can be due to the high rate of bilirubin production in males than females.<xref ref-type="bibr" rid="article-23157.r21">[21]</xref> In 0.5 to 2.4% of infants, breast milk jaundice occurs between days 2 and 5 after birth due to increased enterohepatic circulation of bilirubin, peaks at two weeks, and resolves between 3 to 12 weeks.<xref ref-type="bibr" rid="article-23157.r14">[14]</xref></p>
      </sec>
      <sec id="article-23157.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Jaundice is evident when the serum bilirubin level exceeds 3mg/dL. Gilbert syndrome and Crigler-Najjar syndrome type I and II, are hereditary non-hemolytic unconjugated hyperbilirubinemias that result from the mutations in the UGT1A1 gene and impair bilirubin conjugation. In Gilbert syndrome, UGT1A1 enzyme activity is 10 to 30% of normal, which results in mild unconjugated hyperbilirubinemia with bilirubin levels below 5 mg/dL.<xref ref-type="bibr" rid="article-23157.r22">[22]</xref> The decreased activity of UGT1A1 results from the addition of extra thymine-adenine (TA) repeats in the TATAA box region of the UGT1A1 gene promoter.<xref ref-type="bibr" rid="article-23157.r23">[23]</xref>&#x000a0;Individuals with Gilbert syndrome have a relatively benign course. Crigler-Najjar types I and II syndromes are inherited autosomal recessive disorders that result from the mutations in any one or more of the five exons of the gene that encodes the UGT1A1 enzyme.<xref ref-type="bibr" rid="article-23157.r24">[24]</xref> In Crigler-Najjar type I (CNS1), UGT1A1 enzyme activity is absent, leading to a severe increase in unconjugated bilirubin levels ranging from 20 to 45 mg/dL. In the neonatal period, infants with Crigler-Najjar type I syndrome usually develop bilirubin encephalopathy (Kernicterus) with seizures, opisthotonos, and die from severe neurologic diseases in the absence of treatment.<xref ref-type="bibr" rid="article-23157.r10">[10]</xref></p>
        <p>Individuals with Crigler-Najjar type II (CNS2) have less than 10% of the normal UGT1A1 activity, resulting in bilirubin levels of 5&#x000a0;to 25 mg/dL. Kernicterus is rare in Crigler-Najjar type II, but patients with increased bilirubin levels (greater than 15 mg/dL) have high chances of its occurrence.<xref ref-type="bibr" rid="article-23157.r25">[25]</xref><xref ref-type="bibr" rid="article-23157.r26">[26]</xref>&#x000a0;Kernicterus can occur under stress and with inter-current illnesses. Also, CNS2 therapy with phenobarbital can lower the UCB levels by 25%.<xref ref-type="bibr" rid="article-23157.r27">[27]</xref></p>
      </sec>
      <sec id="article-23157.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Patients with unconjugated hyperbilirubinemia may present with jaundice or other signs, or the condition may be noticed in the asymptomatic patient by the finding of high levels of bilirubin in the serum during routine blood testing. As far as the differential diagnosis of unconjugated hyperbilirubinemia is involved, it requires a detailed history and physical examination of patients for the evaluation. The assessment of the patient&#x02019;s clinical history includes; age at the disease manifestation, ethnic origin/race, hereditary disorder, family history of anemia or jaundice, recently used medications, diet history, and history of liver disease.</p>
        <p>Approximately 50% of neonates present with physiologic jaundice during the first five days after birth. Nonphysiologic, Lucey-Driscoll syndrome, or maternal serum jaundice in neonates results from maternal serum during the initial four days after delivery.<xref ref-type="bibr" rid="article-23157.r12">[12]</xref>&#x000a0;The onset of asymptomatic jaundice usually characterizes the overproduction of bilirubin due to ineffective erythropoiesis (early labeled bilirubin production). Patients with Gilbert syndrome are generally asymptomatic and present with mild or intermittent unconjugated hyperbilirubinemia without any liver disease or hemolysis, and on clinical examination may manifest jaundice. Some nonspecific symptoms, such as fatigue, abdominal cramps, and malaise, are commonly observed in this disease.&#x000a0;Infants with Crigler-Najjar type I syndrome present jaundice in the first few days after birth with neurological sequelae if UCB is greater than 20 mg/dL. By the second week of an infant&#x02019;s life, it rapidly progresses to life-threatening severe jaundice that requires treatment with exchange transfusion, intensive phototherapy, and liver transplantation.<xref ref-type="bibr" rid="article-23157.r28">[28]</xref> However, patients with Crigler-Najjar type II syndrome, are mostly asymptomatic and may rarely present with jaundice and kernicterus. During the physical examination, the color of the skin and sclerae should be examined carefully under light for the evaluation of jaundice. For example, in patients with mild jaundice or hyperbilirubinemia (2&#x000a0;to 3 mg/dL), only scleral icterus can be seen. Also, with hemolytic anemia, there might be anemia and splenomegaly.</p>
      </sec>
      <sec id="article-23157.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>The initial assessment of the patient presenting with jaundice depends on whether hyperbilirubinemia is the result of unconjugated or conjugated bilirubin. A urine test positive for bilirubin indicates conjugated hyperbilirubinemia. Conjugated bilirubin is soluble in water; therefore, it can be excreted via urine but not unconjugated bilirubin due to water insolubility. Further, first-line laboratory testing should include measurement of the serum total bilirubin levels with fractionation (direct with indirect obtained by subtraction from total), followed by serum aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase, and &#x003b3;-glutamyl transpeptidase (GGT) levels, complete blood count (CBC) with an examination of the smear, a reticulocyte count, a direct Coombs test, lactate dehydrogenase (LDH) and haptoglobin levels.<xref ref-type="bibr" rid="article-23157.r29">[29]</xref>&#x000a0;Jaundice, with a toxic appearance, fever, or abnormal count of white blood cells indicates sepsis that requires prompt evaluation and adequate treatment.&#x000a0; The increased levels of AST and ALT are markers of hepatocyte damage/injury. However, increased levels of alkaline phosphatase and &#x003b3;-glutamyltransferase suggest cholestasis.</p>
        <p>A complete blood count is a beneficial test for the determination of hemolysis, which is characterized by the presence of damaged red blood cells and increased reticulocytes on the smear. In patients, when the serum total bilirubin levels exceed 3.0 mg/dL, jaundice becomes clinically apparent. Hyperbilirubinemia is unconjugated when the conjugated bilirubin level is less than 15% of the TB. While in conjugated hyperbilirubinemia, conjugated bilirubin level is high and more than 20% of the total bilirubin. Generally, patients with carotenemia also present yellow skin but have no elevation in serum bilirubin levels. During the physical examination, carotenemia due to excess carotene intake, e.g., carrots, peaches, etc., can be distinguished from jaundice due to the absence of scleral icterus in carotenemia and with the pigmentation of soles and palms and other areas. Computerized axial tomography (CT) and ultrasonography scanning are useful tools in differentiating cholestasis (intra-hepatic and extra-hepatic) from hepatocellular disease in the assessment of a patient with conjugated hyperbilirubinemia, which is not the focus of the review.</p>
      </sec>
      <sec id="article-23157.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>
<bold>Neonatal Jaundice</bold>
</p>
        <p>In most cases of mild neonatal jaundice, no treatment is necessary, and it resolves on its own within a few weeks. In cases of moderate or severe jaundice (TB&#x000a0;over 15 mg/dL), phototherapy is a safe option. During phototherapy, the infant&#x02019;s skin is exposed to light in the blue-green spectrum (460-490 nm) in a way that transforms bilirubin into lumirubin, a water-soluble isomer, and reduces its toxicity by increasing its elimination in both the urine and stool.<xref ref-type="bibr" rid="article-23157.r30">[30]</xref><xref ref-type="bibr" rid="article-23157.r31">[31]</xref>&#x000a0;It is crucial to maintain proper hydration and urine output during phototherapy.<xref ref-type="bibr" rid="article-23157.r17">[17]</xref><xref ref-type="bibr" rid="article-23157.r32">[32]</xref>&#x000a0;Unfiltered sunlight has ultraviolet light (&#x0003c;400 nm) which increases the risk of sunburn and skin cancers. Hence unfiltered sunlight is not utilized for phototherapy.</p>
        <p>In some cases, infants carry antibodies from the mother that can result in the quick breakdown of neonatal red blood cells (due to differences in the blood type), intravenous transfusion of an immunoglobulin (IVIG) that can reduce the levels of antibodies may be the choice of treatment. In a rare instance of severe neonatal jaundice, when other treatments do not work, exchange transfusion of blood may be performed.<xref ref-type="bibr" rid="article-23157.r33">[33]</xref> In this procedure, a small amount of infant&#x02019;s blood repeatedly gets withdrawn and replaced with donor blood to dilute the levels of bilirubin and maternal antibodies. Total bilirubin decreases to 50-75 percent of the pre-exchange level with double volume exchange transfusion.&#x000a0;</p>
        <p>
<bold>Gilbert Syndrome</bold>
</p>
        <p>The most crucial part for clinicians in the management and care of patients with Gilbert syndrome (GS) is to recognize that it is relatively benign with a good prognosis. The diagnosis of GS requires normal liver function tests, elevated bilirubin levels, and genetic testing to confirm the disorder further. Owing to the benign and inconsequential nature of this syndrome, the use of medications is not justified for its treatment. There exists an increased risk of side effects and toxicity from the use of certain drugs such as acetaminophen and irinotecan that are conjugated by the liver.<xref ref-type="bibr" rid="article-23157.r5">[5]</xref>&#x000a0;Phenobarbital has been shown to normalize bilirubin levels.&#x000a0;</p>
        <p>
<bold>Crigler-Najjar Type II Syndrome</bold>
</p>
        <p>Patients with Crigler-Najjar syndrome type II respond to phenobarbital therapy. Since CNS2 is milder, phenobarbital is effective in reducing plasma bilirubin levels in these patients by 25 %. In some cases, patients with severe hyperbilirubinemia may need phototherapy or exchange transfusions. However, often, patients affected with type II syndrome may not require any therapy but may need routine monitoring. The goal is to maintain TB below 15 mg/dL.</p>
        <p>
<bold>Crigler-Najjar Type I Syndrome</bold>
</p>
        <p>Unlike CNS2, patients with CNS1 do not respond to phenobarbital therapy due to the absence of the enzyme. Rapid treatment of kernicterus is needed to prevent devastating neurologic sequelae. The emergent treatment for bilirubin encephalopathy relies on repeated plasma exchange transfusions followed by long-term phototherapy.<xref ref-type="bibr" rid="article-23157.r28">[28]</xref> The process of plasma exchange transfusion flushes out bilirubin-saturated albumin and provides free protein, which lures bilirubin from the tissues. To maintain the levels of unconjugated hyperbilirubinemia below the neurotoxic threshold, patients with Crigler-Najjar syndrome type I generally need phototherapy for 10&#x000a0;to 12 hours a day. Phototherapy helps in converting bilirubin to more water-soluble bilirubin isoforms that can get excreted in the urine. The efficacy of phototherapy is dose-dependent and depends on the intensity of light, exposure of the body surface, or reflecting mirrors used. Short-term complications of phototherapy are reduced cardiac output and renal perfusion, hyperthermia, increased cerebral perfusion, oxidative stress, skin rash, breastfeeding interruption, and rarely bronze baby syndrome.<xref ref-type="bibr" rid="article-23157.r30">[30]</xref>&#x000a0;The bronze baby syndrome is a rare, reversible dark, grayish-brown skin, serum, and urine discoloration, caused by bronze pigmented photoisomers, identified in infants treated with phototherapy.<xref ref-type="bibr" rid="article-23157.r34">[34]</xref>&#x000a0;Pigments are eliminated slowly after phototherapy discontinuation, and resolution is seen within weeks without any sequelae.<xref ref-type="bibr" rid="article-23157.r35">[35]</xref>&#x000a0;&#x000a0;&#x000a0;Some side effects associated with long-term phototherapy are restriction of activity, delay in normal development, diarrhea, reduced weight gain, problems in maintaining body temperature, and risk of seizures (greater in boys).<xref ref-type="bibr" rid="article-23157.r36">[36]</xref></p>
        <p>Oral calcium phosphate may be a valuable adjuvant to phototherapy in Crigler-Najjar type I syndrome, by interrupting the enterohepatic circulation of bilirubin.<xref ref-type="bibr" rid="article-23157.r37">[37]</xref> Treatment with inhibitors of heme oxygenase (tin-mesoporphyrin) helps decrease plasma bilirubin levels but is not recommended for the long term owing to their side effects.<xref ref-type="bibr" rid="article-23157.r38">[38]</xref></p>
        <p>Plasmapheresis is also being employed to lower bilirubin levels in the blood rapidly.<xref ref-type="bibr" rid="article-23157.r28">[28]</xref>&#x000a0;In this procedure, unwanted substances (toxins and plasma components) get removed from the blood, and plasma gets replaced with other human plasma before transfusing blood back into the patient.&#x000a0;</p>
        <p>In patients with Crigler-Najjar syndrome type I, orthotopic liver transplantation may be considered a definite form of therapy and should be performed before the onset of neurologic damage.<xref ref-type="bibr" rid="article-23157.r39">[39]</xref>&#x000a0;Transplantation of hepatocytes is being investigated as an alternative to liver transplantation.<xref ref-type="bibr" rid="article-23157.r40">[40]</xref> Gene therapy is another approach for the treatment of CNS1. Significant improvement leading to the life-long cure of the disease can be achieved clinically with gene therapy by replacing a defective gene with a normal one.<xref ref-type="bibr" rid="article-23157.r41">[41]</xref>&#x000a0;Presently gene transfer that can reduce the bilirubin levels for several years by partially replacing the gene controlling bilirubin glucuronosyltransferase activity in the patients is being considered for treatment of CNS1. Long-term monitoring is important for patients at risk for a sudden increase in serum bilirubin levels.</p>
        <p>
<bold>Pharmacologic management</bold>
</p>
        <p>Patients with Crigler-Najjar type II syndrome do not require any treatment and can be managed with phenobarbital. Also, for Gilbert syndrome, no medical therapy is needed, and phenobarbital has been effectively shown to decrease bilirubin production. The common medications used for the treatment of patients with Crigler-Najjar type I syndrome are phenobarbital, calcium (infusions), ursodeoxycholic acid, metalloporphyrins, chlorpromazine, and cholestyramine.&#x000a0;&#x000a0;</p>
        <p>Phenobarbital increases both the conjugation and excretion of bilirubin by stimulating the gene for the UGT1A1 enzyme, which induces the production of conjugated bilirubin and thereby reduces the serum bilirubin levels by 25%. Ursodeoxycholic acid increases the flow of the bile, the elimination of bile into the gastrointestinal tract, thereby reducing the total serum bilirubin levels.<xref ref-type="bibr" rid="article-23157.r42">[42]</xref></p>
        <p>Metalloporphyrins like tin-mesoporphyrin (SnMp) inhibit the activity of the heme oxygenase enzyme, which is a rate-limiting step in the production of bilirubin from heme metabolism.<xref ref-type="bibr" rid="article-23157.r43">[43]</xref><xref ref-type="bibr" rid="article-23157.r44">[44]</xref> They reduce the necessity of phototherapy and the need for continued hospitalization.<xref ref-type="bibr" rid="article-23157.r45">[45]</xref><xref ref-type="bibr" rid="article-23157.r46">[46]</xref><xref ref-type="bibr" rid="article-23157.r47">[47]</xref>&#x000a0;Calcium (infusions) like calcium phosphate bind to bilirubin in the gut and increases bilirubin&#x02019;s fecal excretion.&#x000a0;</p>
      </sec>
      <sec id="article-23157.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Unconjugated hyperbilirubinemia can be caused by dysregulation in bilirubin metabolism that includes bilirubin production, uptake in hepatocytes, and conjugation. The clinician should distinguish unconjugated hyperbilirubinemia from other conditions with similar clinical manifestations. Hemolytic anemias and resorption of hematoma significantly increase the levels of unconjugated bilirubin. Hemolytic anemias may lead to a mild increase in bilirubin levels with or without clinical symptoms. Hemolytic disorders such as glucose-6-phosphate dehydrogenase (G6PD) deficiency, sickle cell anemia, thalassemia, iso-immune mediated hemolysis, and autoimmune disorders should be a consideration during diagnosis.<xref ref-type="bibr" rid="article-23157.r48">[48]</xref></p>
        <p>Inherited disorders of the enzyme glucuronosyltransferase (UGT1A1) such as Gilbert syndrome and Crigler-Najjar syndromes (CNS1 and CNS2), may impede the complete conjugation of bilirubin and thereby cause varying degrees of unconjugated hyperbilirubinemia, depending on inhibition of enzyme with each disease. In addition to inherited disorders, other conditions such as portosystemic shunts, congestive heart failure, liver damage, dyserythropoiesis, and hyperthyroidism can also contribute to impaired bilirubin conjugation and should merit consideration during diagnosis. Additional considerations in the diagnosis of unconjugated hyperbilirubinemia include drugs interfering with bilirubin uptake or conjugation (rifampicin, probenecid, or other rifamycin antibiotics, ketoconazole, amitryptiline, and protease inhibitors), chronic liver diseases, thyrotoxicosis, infections, and physiologic neonatal jaundice resulting from the immature conjugating ability of the UGT1A1 enzyme.<xref ref-type="bibr" rid="article-23157.r49">[49]</xref><xref ref-type="bibr" rid="article-23157.r50">[50]</xref><xref ref-type="bibr" rid="article-23157.r51">[51]</xref></p>
      </sec>
      <sec id="article-23157.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The prognosis in neonatal jaundice is excellent if the patient receives the recommended standard of care. In most cases, jaundice gets better within one or two weeks. In some cases, such as breast milk jaundice and maternal serum jaundice, jaundice can persist for several weeks. Thus, the patient&#x02019;s serum bilirubin levels need to be monitored closely, with adequate adjustments in treatment made accordingly to prevent persistent hyperbilirubinemia and thereby its consequence, kernicterus and bilirubin induced neurologic dysfunction. The prognosis of patients with ineffective erythropoiesis, which causes the overproduction of bilirubin is also excellent and depends on the cause. Patients with Crigler Najjar syndrome type I have a high risk of kernicterus, and thereby present a poor prognosis and need intensive, aggressive management. However, the prognosis of Crigler Najjar syndrome type II patients is more favorable and rarely associated with kernicterus. Gilbert syndrome is a benign condition, and patients with this syndrome have an excellent prognosis. An individual affected with this inherited disorder can live a normal life. Recent studies have shown that a person with Gilbert syndrome has a low risk of cardiovascular diseases, possibly due to an increase in bilirubin ameliorating oxidative stress.<xref ref-type="bibr" rid="article-23157.r52">[52]</xref><xref ref-type="bibr" rid="article-23157.r53">[53]</xref>&#x000a0;Long-term survival is identified in patients that had liver transplantation.<xref ref-type="bibr" rid="article-23157.r54">[54]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-23157.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Extreme hyperbilirubinemia (TB of 25&#x000a0;to 30 mg/dL) can cause bilirubin encephalopathy, Kernicterus, which is usually characterized by the deposition of unconjugated bilirubin (yellow stain) in brain cells. Neuronal necrosis/damage occurs in the basal ganglia, hippocampus, hypothalamic nuclei,&#x000a0;diencephalon, midbrain responsible for neurohumoral and electrolyte control, brainstem nuclei accounting for oculomotor and auditory function, and in the cerebellum depositing as a bilirubin-phosphatidylcholine precipitate. Vision, hearing, speech, cognition, gait, and language are typically affected.<xref ref-type="bibr" rid="article-23157.r55">[55]</xref><xref ref-type="bibr" rid="article-23157.r56">[56]</xref><xref ref-type="bibr" rid="article-23157.r57">[57]</xref><xref ref-type="bibr" rid="article-23157.r58">[58]</xref> Clinical manifestations include cerebral palsy, deafness, seizures, abnormalities of the gaze, and hypoplasia of the dental enamel.<xref ref-type="bibr" rid="article-23157.r59">[59]</xref></p>
      </sec>
      <sec id="article-23157.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Patients and their families should receive education regarding jaundice and its consequences. Patients need to understand the role of unconjugated hyperbilirubinemia in the manifestation of jaundice and its severity. Patients require counseling regarding the physical appearance or symptoms of jaundice. In the case of neonatal jaundice, parents will need to know about the cause of physiologic or non-physiologic jaundice and the treatment options available for it. Patients with any change in mental or neural behavior should immediately consult with a physician. Future parents with a family history of inherited Crigler-Najjar syndromes should seek genetic counseling. Education on the autosomal recessive pattern of inheritance must be provided to the patients and families.&#x000a0;</p>
      </sec>
      <sec id="article-23157.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>The treatment of unconjugated hyperbilirubinemia requires interprofessional teamwork, as it can result from multiple disorders or diseases. As far as the differential diagnoses of unconjugated hyperbilirubinemia are involved, it necessitates good coordination between primary care physicians, gastroenterologists, hematologists, a pediatrician, and other specialists. A detailed history of the patient's medications that causes liver dysfunction is critical for the treatment. The outcome of most patients with unconjugated hyperbilirubinemia is excellent when they receive the treatment according to the accepted guidelines with no or minimal neural and developmental sequelae.<xref ref-type="bibr" rid="article-23157.r60">[60]</xref>&#x000a0;Crigler Najjar syndromes, especially Type 1 on the other hand have a high risk of the life-threatening kernicterus that requires lifelong monitoring and treatment.</p>
      </sec>
      <sec id="article-23157.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=23157&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=23157">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/health/unconjugated-hyperbilirubinemia/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=23157">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/23157/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=23157">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-23157.s15">
        <fig id="article-23157.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Metabolic Pathway for Bilirubin in the Hepatocyte. Bilirubin-G corresponds to bilirubin glucuronate; the donor is uridine diphosphate glucuronic acid (UDP-GA). This is catalyzed by the enzyme uridine diphosphate-glucuronyltransferase (UGT1A1). Gilbert and Crigler-Najjar syndrome is associated with decreases in UGT1A1 activity. Glutathione-S-transferase (GST) is a carrier protein that assists bilirubin uptake into the cytosol and may be implicated in Rotor syndrome. Contributed by R Kabir, MD</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Kabir_Rotor__Syndrome" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-23157.s16">
        <title>References</title>
        <ref id="article-23157.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fargo</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Grogan</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Saguil</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of Jaundice in Adults.</article-title>
            <source>Am Fam Physician</source>
            <year>2017</year>
            <month>Feb</month>
            <day>01</day>
            <volume>95</volume>
            <issue>3</issue>
            <fpage>164</fpage>
            <page-range>164-168</page-range>
            <pub-id pub-id-type="pmid">28145671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roche</surname>
                <given-names>SP</given-names>
              </name>
              <name>
                <surname>Kobos</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Jaundice in the adult patient.</article-title>
            <source>Am Fam Physician</source>
            <year>2004</year>
            <month>Jan</month>
            <day>15</day>
            <volume>69</volume>
            <issue>2</issue>
            <fpage>299</fpage>
            <page-range>299-304</page-range>
            <pub-id pub-id-type="pmid">14765767</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Memon</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Weinberger</surname>
                <given-names>BI</given-names>
              </name>
              <name>
                <surname>Hegyi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Aleksunes</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>Inherited disorders of bilirubin clearance.</article-title>
            <source>Pediatr Res</source>
            <year>2016</year>
            <month>Mar</month>
            <volume>79</volume>
            <issue>3</issue>
            <fpage>378</fpage>
            <page-range>378-86</page-range>
            <pub-id pub-id-type="pmid">26595536</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Radlovi&#x00107;</surname>
                <given-names>N</given-names>
              </name>
            </person-group>
            <article-title>Hereditary hyperbilirubinemias.</article-title>
            <source>Srp Arh Celok Lek</source>
            <year>2014</year>
            <season>Mar-Apr</season>
            <volume>142</volume>
            <issue>3-4</issue>
            <fpage>257</fpage>
            <page-range>257-60</page-range>
            <pub-id pub-id-type="pmid">24839786</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r5">
          <label>5</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ramakrishnan</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bittar</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Jialal</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <chapter-title>Impaired Bilirubin Conjugation</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>9</month>
            <day>12</day>
            <pub-id pub-id-type="pmid">29494090</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Franchini</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Targher</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Lippi</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Serum bilirubin levels and cardiovascular disease risk: a Janus Bifrons?</article-title>
            <source>Adv Clin Chem</source>
            <year>2010</year>
            <volume>50</volume>
            <fpage>47</fpage>
            <page-range>47-63</page-range>
            <pub-id pub-id-type="pmid">20521440</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000ed;tek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Schwertner</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>The heme catabolic pathway and its protective effects on oxidative stress-mediated diseases.</article-title>
            <source>Adv Clin Chem</source>
            <year>2007</year>
            <volume>43</volume>
            <fpage>1</fpage>
            <page-range>1-57</page-range>
            <pub-id pub-id-type="pmid">17249379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>V&#x000ed;tek</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Ostrow</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Bilirubin chemistry and metabolism; harmful and protective aspects.</article-title>
            <source>Curr Pharm Des</source>
            <year>2009</year>
            <volume>15</volume>
            <issue>25</issue>
            <fpage>2869</fpage>
            <page-range>2869-83</page-range>
            <pub-id pub-id-type="pmid">19754364</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jedlitschky</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Hoffmann</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kroemer</surname>
                <given-names>HK</given-names>
              </name>
            </person-group>
            <article-title>Structure and function of the MRP2 (ABCC2) protein and its role in drug disposition.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>2</volume>
            <issue>3</issue>
            <fpage>351</fpage>
            <page-range>351-66</page-range>
            <pub-id pub-id-type="pmid">16863439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dennery</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Seidman</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Neonatal hyperbilirubinemia.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Feb</month>
            <day>22</day>
            <volume>344</volume>
            <issue>8</issue>
            <fpage>581</fpage>
            <page-range>581-90</page-range>
            <pub-id pub-id-type="pmid">11207355</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kenwright</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Levi</surname>
                <given-names>AJ</given-names>
              </name>
            </person-group>
            <article-title>Sites of competition in the selective hepatic uptake of rifamycin-SV, flavaspidic acid, bilirubin, and bromsulphthalein.</article-title>
            <source>Gut</source>
            <year>1974</year>
            <month>Mar</month>
            <volume>15</volume>
            <issue>3</issue>
            <fpage>220</fpage>
            <page-range>220-6</page-range>
            <pub-id pub-id-type="pmid">4842968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ARIAS</surname>
                <given-names>IM</given-names>
              </name>
              <name>
                <surname>WOLFSON</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>LUCEY</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>MCKAY</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>TRANSIENT FAMILIAL NEONATAL HYPERBILIRUBINEMIA.</article-title>
            <source>J Clin Invest</source>
            <year>1965</year>
            <month>Sep</month>
            <volume>44</volume>
            <issue>9</issue>
            <fpage>1442</fpage>
            <page-range>1442-50</page-range>
            <pub-id pub-id-type="pmid">14332157</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Grunebaum</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Amir</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Merlob</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Mimouni</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Varsano</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Breast mild jaundice: natural history, familial incidence and late neurodevelopmental outcome of the infant.</article-title>
            <source>Eur J Pediatr</source>
            <year>1991</year>
            <month>Feb</month>
            <volume>150</volume>
            <issue>4</issue>
            <fpage>267</fpage>
            <page-range>267-70</page-range>
            <pub-id pub-id-type="pmid">2029918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maisels</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Clune</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Coleman</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Gendelman</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kendall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McManus</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Smyth</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>The natural history of jaundice in predominantly breastfed infants.</article-title>
            <source>Pediatrics</source>
            <year>2014</year>
            <month>Aug</month>
            <volume>134</volume>
            <issue>2</issue>
            <fpage>e340</fpage>
            <page-range>e340-5</page-range>
            <pub-id pub-id-type="pmid">25049352</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maisels</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Kring</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Length of stay, jaundice, and hospital readmission.</article-title>
            <source>Pediatrics</source>
            <year>1998</year>
            <month>Jun</month>
            <volume>101</volume>
            <issue>6</issue>
            <fpage>995</fpage>
            <page-range>995-8</page-range>
            <pub-id pub-id-type="pmid">9606225</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chando</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Everett</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Patten</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Dehal</surname>
                <given-names>SS</given-names>
              </name>
              <name>
                <surname>Humphreys</surname>
                <given-names>WG</given-names>
              </name>
            </person-group>
            <article-title>In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation.</article-title>
            <source>Drug Metab Dispos</source>
            <year>2005</year>
            <month>Nov</month>
            <volume>33</volume>
            <issue>11</issue>
            <fpage>1729</fpage>
            <page-range>1729-39</page-range>
            <pub-id pub-id-type="pmid">16118329</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Woodgate</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jardine</surname>
                <given-names>LA</given-names>
              </name>
            </person-group>
            <article-title>Neonatal jaundice: phototherapy.</article-title>
            <source>BMJ Clin Evid</source>
            <year>2015</year>
            <month>May</month>
            <day>22</day>
            <volume>2015</volume>
            <pub-id pub-id-type="pmid">25998618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ebrahimi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahim</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Crigler-Najjar Syndrome: Current Perspectives and the Application of Clinical Genetics.</article-title>
            <source>Endocr Metab Immune Disord Drug Targets</source>
            <year>2018</year>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>201</fpage>
            <page-range>201-211</page-range>
            <pub-id pub-id-type="pmid">29237388</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lampe</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Bigler</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Horner</surname>
                <given-names>NK</given-names>
              </name>
              <name>
                <surname>Potter</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>UDP-glucuronosyltransferase (UGT1A1*28 and UGT1A6*2) polymorphisms in Caucasians and Asians: relationships to serum bilirubin concentrations.</article-title>
            <source>Pharmacogenetics</source>
            <year>1999</year>
            <month>Jun</month>
            <volume>9</volume>
            <issue>3</issue>
            <fpage>341</fpage>
            <page-range>341-9</page-range>
            <pub-id pub-id-type="pmid">10471066</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Clementi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Di Gianantonio</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Fabris</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Forabosco</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Strazzabosco</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Tenconi</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okolicsanyi</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Inheritance of hyperbilirubinemia: evidence for a major autosomal recessive gene.</article-title>
            <source>Dig Liver Dis</source>
            <year>2007</year>
            <month>Apr</month>
            <volume>39</volume>
            <issue>4</issue>
            <fpage>351</fpage>
            <page-range>351-5</page-range>
            <pub-id pub-id-type="pmid">17347060</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Muraca</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fevery</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Influence of sex and sex steroids on bilirubin uridine diphosphate-glucuronosyltransferase activity of rat liver.</article-title>
            <source>Gastroenterology</source>
            <year>1984</year>
            <month>Aug</month>
            <volume>87</volume>
            <issue>2</issue>
            <fpage>308</fpage>
            <page-range>308-13</page-range>
            <pub-id pub-id-type="pmid">6428963</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Auclair</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hakim</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boivin</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Troube</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Boucherot</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Bilirubin and paranitrophenol glucuronyl transferase activities of the liver in patients with Gilbert's syndrome An attempt at a biochemical breakdown of the Gilbert's syndrome.</article-title>
            <source>Enzyme</source>
            <year>1976</year>
            <volume>21</volume>
            <issue>2</issue>
            <fpage>97</fpage>
            <page-range>97-107</page-range>
            <pub-id pub-id-type="pmid">816648</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bosma</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Chowdhury</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gantla</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>de Boer</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Oostra</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Lindhout</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Tytgat</surname>
                <given-names>GN</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Oude Elferink</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome.</article-title>
            <source>N Engl J Med</source>
            <year>1995</year>
            <month>Nov</month>
            <day>02</day>
            <volume>333</volume>
            <issue>18</issue>
            <fpage>1171</fpage>
            <page-range>1171-5</page-range>
            <pub-id pub-id-type="pmid">7565971</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Erps</surname>
                <given-names>LT</given-names>
              </name>
              <name>
                <surname>Ritter</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Hersh</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Blossom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>NC</given-names>
              </name>
              <name>
                <surname>Owens</surname>
                <given-names>IS</given-names>
              </name>
            </person-group>
            <article-title>Identification of two single base substitutions in the UGT1 gene locus which abolish bilirubin uridine diphosphate glucuronosyltransferase activity in vitro.</article-title>
            <source>J Clin Invest</source>
            <year>1994</year>
            <month>Feb</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>564</fpage>
            <page-range>564-70</page-range>
            <pub-id pub-id-type="pmid">7906695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevenson</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Vreman</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
            </person-group>
            <article-title>Bilirubin production and the risk of bilirubin neurotoxicity.</article-title>
            <source>Semin Perinatol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>121</fpage>
            <page-range>121-6</page-range>
            <pub-id pub-id-type="pmid">21641484</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sticova</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Jirsa</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>New insights in bilirubin metabolism and their clinical implications.</article-title>
            <source>World J Gastroenterol</source>
            <year>2013</year>
            <month>Oct</month>
            <day>14</day>
            <volume>19</volume>
            <issue>38</issue>
            <fpage>6398</fpage>
            <page-range>6398-407</page-range>
            <pub-id pub-id-type="pmid">24151358</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Trotman</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Roy-Chowdhury</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Malet</surname>
                <given-names>PF</given-names>
              </name>
              <name>
                <surname>Rosato</surname>
                <given-names>EF</given-names>
              </name>
            </person-group>
            <article-title>Effect of phenobarbital on serum and biliary parameters in a patient with Crigler-Najjar syndrome, type II and acquired cholestasis.</article-title>
            <source>Dig Dis Sci</source>
            <year>1983</year>
            <month>Aug</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>753</fpage>
            <page-range>753-62</page-range>
            <pub-id pub-id-type="pmid">6872808</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strauss</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Ahlfors</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Soltys</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mazareigos</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>Young</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bowser</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Fox</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Squires</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>McKiernan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Brigatti</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Puffenberger</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Carson</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Vreman</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>Crigler-Najjar Syndrome Type 1: Pathophysiology, Natural History, and Therapeutic Frontier.</article-title>
            <source>Hepatology</source>
            <year>2020</year>
            <month>Jun</month>
            <volume>71</volume>
            <issue>6</issue>
            <fpage>1923</fpage>
            <page-range>1923-1939</page-range>
            <pub-id pub-id-type="pmid">31553814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Winger</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Michelfelder</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Diagnostic approach to the patient with jaundice.</article-title>
            <source>Prim Care</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>38</volume>
            <issue>3</issue>
            <fpage>469</fpage>
            <page-range>469-82; viii</page-range>
            <pub-id pub-id-type="pmid">21872092</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hansen</surname>
                <given-names>TWR</given-names>
              </name>
              <name>
                <surname>Maisels</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Ebbesen</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Vreman</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Bhutani</surname>
                <given-names>VK</given-names>
              </name>
            </person-group>
            <article-title>Sixty years of phototherapy for neonatal jaundice - from serendipitous observation to standardized treatment and rescue for millions.</article-title>
            <source>J Perinatol</source>
            <year>2020</year>
            <month>Feb</month>
            <volume>40</volume>
            <issue>2</issue>
            <fpage>180</fpage>
            <page-range>180-193</page-range>
            <pub-id pub-id-type="pmid">31420582</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ennever</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Costarino</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Polin</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Speck</surname>
                <given-names>WT</given-names>
              </name>
            </person-group>
            <article-title>Rapid clearance of a structural isomer of bilirubin during phototherapy.</article-title>
            <source>J Clin Invest</source>
            <year>1987</year>
            <month>Jun</month>
            <volume>79</volume>
            <issue>6</issue>
            <fpage>1674</fpage>
            <page-range>1674-8</page-range>
            <pub-id pub-id-type="pmid">3584465</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sherbiny</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Youssef</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sherbini</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>El-Behedy</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sherief</surname>
                <given-names>LM</given-names>
              </name>
            </person-group>
            <article-title>High-intensity light-emitting diode vs fluorescent tubes for intensive phototherapy in neonates.</article-title>
            <source>Paediatr Int Child Health</source>
            <year>2016</year>
            <month>May</month>
            <volume>36</volume>
            <issue>2</issue>
            <fpage>127</fpage>
            <page-range>127-33</page-range>
            <pub-id pub-id-type="pmid">25844870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Flaherman</surname>
                <given-names>VJ</given-names>
              </name>
              <name>
                <surname>Kuzniewicz</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>GJ</given-names>
              </name>
              <name>
                <surname>Newman</surname>
                <given-names>TB</given-names>
              </name>
            </person-group>
            <article-title>Total serum bilirubin exceeding exchange transfusion thresholds in the setting of universal screening.</article-title>
            <source>J Pediatr</source>
            <year>2012</year>
            <month>May</month>
            <volume>160</volume>
            <issue>5</issue>
            <fpage>796</fpage>
            <page-range>796-800.e1</page-range>
            <pub-id pub-id-type="pmid">22133423</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rubaltelli</surname>
                <given-names>FF</given-names>
              </name>
              <name>
                <surname>Da Riol</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>D'Amore</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Jori</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The bronze baby syndrome: evidence of increased tissue concentration of copper porphyrins.</article-title>
            <source>Acta Paediatr</source>
            <year>1996</year>
            <month>Mar</month>
            <volume>85</volume>
            <issue>3</issue>
            <fpage>381</fpage>
            <page-range>381-4</page-range>
            <pub-id pub-id-type="pmid">8696003</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tan</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Jacob</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>The bronze baby syndrome.</article-title>
            <source>Acta Paediatr Scand</source>
            <year>1982</year>
            <month>May</month>
            <volume>71</volume>
            <issue>3</issue>
            <fpage>409</fpage>
            <page-range>409-14</page-range>
            <pub-id pub-id-type="pmid">7136654</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Kuzniewicz</surname>
                <given-names>MW</given-names>
              </name>
              <name>
                <surname>Grimes</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>McCulloch</surname>
                <given-names>CE</given-names>
              </name>
            </person-group>
            <article-title>Childhood Seizures After Phototherapy.</article-title>
            <source>Pediatrics</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>142</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">30249623</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Van Der Veere</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Schoemaker</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Van Der Meer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Elferink</surname>
                <given-names>RP</given-names>
              </name>
            </person-group>
            <article-title>Influence of dietary calcium phosphate on the disposition of bilirubin in rats with unconjugated hyperbilirubinemia.</article-title>
            <source>Hepatology</source>
            <year>1996</year>
            <month>Sep</month>
            <volume>24</volume>
            <issue>3</issue>
            <fpage>620</fpage>
            <page-range>620-6</page-range>
            <pub-id pub-id-type="pmid">8781334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Evans</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Neonatal jaundice.</article-title>
            <source>BMJ Clin Evid</source>
            <year>2007</year>
            <month>Jun</month>
            <day>01</day>
            <volume>2007</volume>
            <pub-id pub-id-type="pmid">19454091</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schauer</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Stangl</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lang</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zimmermann</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chouker</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gerbes</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>Schildberg</surname>
                <given-names>FW</given-names>
              </name>
              <name>
                <surname>Rau</surname>
                <given-names>HG</given-names>
              </name>
            </person-group>
            <article-title>Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation.</article-title>
            <source>J Pediatr Surg</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>38</volume>
            <issue>8</issue>
            <fpage>1227</fpage>
            <page-range>1227-31</page-range>
            <pub-id pub-id-type="pmid">12891498</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ambrosino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Varotto</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Strom</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Guariso</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Franchin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Miotto</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Caenazzo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Basso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Carraro</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Valente</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>D'Amico</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Zancan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>D'Antiga</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1.</article-title>
            <source>Cell Transplant</source>
            <year>2005</year>
            <volume>14</volume>
            <issue>2-3</issue>
            <fpage>151</fpage>
            <page-range>151-7</page-range>
            <pub-id pub-id-type="pmid">15881424</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Birraux</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Menzel</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Wildhaber</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Jond</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Chardot</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>A step toward liver gene therapy: efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors.</article-title>
            <source>Transplantation</source>
            <year>2009</year>
            <month>Apr</month>
            <day>15</day>
            <volume>87</volume>
            <issue>7</issue>
            <fpage>1006</fpage>
            <page-range>1006-12</page-range>
            <pub-id pub-id-type="pmid">19352119</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Honar</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ghashghaei Saadi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Saki</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pishva</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Shakibazad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Hosseini Teshnizi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Effect of Ursodeoxycholic Acid on Indirect Hyperbilirubinemia in Neonates Treated With Phototherapy.</article-title>
            <source>J Pediatr Gastroenterol Nutr</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>62</volume>
            <issue>1</issue>
            <fpage>97</fpage>
            <page-range>97-100</page-range>
            <pub-id pub-id-type="pmid">26020375</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r43">
          <label>43</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Valaes</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Petmezaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Henschke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kappas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Control of jaundice in preterm newborns by an inhibitor of bilirubin production: studies with tin-mesoporphyrin.</article-title>
            <source>Pediatrics</source>
            <year>1994</year>
            <month>Jan</month>
            <volume>93</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-11</page-range>
            <pub-id pub-id-type="pmid">8265301</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kappas</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Control of heme metabolism with synthetic metalloporphyrins.</article-title>
            <source>J Clin Invest</source>
            <year>1986</year>
            <month>Feb</month>
            <volume>77</volume>
            <issue>2</issue>
            <fpage>335</fpage>
            <page-range>335-9</page-range>
            <pub-id pub-id-type="pmid">3511095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Suresh</surname>
                <given-names>GK</given-names>
              </name>
              <name>
                <surname>Martin</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Soll</surname>
                <given-names>RF</given-names>
              </name>
            </person-group>
            <article-title>Metalloporphyrins for treatment of unconjugated hyperbilirubinemia in neonates.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2003</year>
            <issue>2</issue>
            <fpage>CD004207</fpage>
            <pub-id pub-id-type="pmid">12804504</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r46">
          <label>46</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bhutani</surname>
                <given-names>VK</given-names>
              </name>
              <name>
                <surname>Poland</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meloy</surname>
                <given-names>LD</given-names>
              </name>
              <name>
                <surname>Hegyi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Fanaroff</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Maisels</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <article-title>Clinical trial of tin mesoporphyrin to prevent neonatal hyperbilirubinemia.</article-title>
            <source>J Perinatol</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>7</issue>
            <fpage>533</fpage>
            <page-range>533-9</page-range>
            <pub-id pub-id-type="pmid">26938918</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r47">
          <label>47</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Martinez</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Garcia</surname>
                <given-names>HO</given-names>
              </name>
              <name>
                <surname>Otheguy</surname>
                <given-names>LE</given-names>
              </name>
              <name>
                <surname>Drummond</surname>
                <given-names>GS</given-names>
              </name>
              <name>
                <surname>Kappas</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Control of severe hyperbilirubinemia in full-term newborns with the inhibitor of bilirubin production Sn-mesoporphyrin.</article-title>
            <source>Pediatrics</source>
            <year>1999</year>
            <month>Jan</month>
            <volume>103</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-5</page-range>
            <pub-id pub-id-type="pmid">9917431</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r48">
          <label>48</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kaplan</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Beutler</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Vreman</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Hammerman</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Levy-Lahad</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Renbaum</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Stevenson</surname>
                <given-names>DK</given-names>
              </name>
            </person-group>
            <article-title>Neonatal hyperbilirubinemia in glucose-6-phosphate dehydrogenase-deficient heterozygotes.</article-title>
            <source>Pediatrics</source>
            <year>1999</year>
            <month>Jul</month>
            <volume>104</volume>
            <issue>1 Pt 1</issue>
            <fpage>68</fpage>
            <page-range>68-74</page-range>
            <pub-id pub-id-type="pmid">10390262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r49">
          <label>49</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnston</surname>
                <given-names>DE</given-names>
              </name>
            </person-group>
            <article-title>Special considerations in interpreting liver function tests.</article-title>
            <source>Am Fam Physician</source>
            <year>1999</year>
            <month>Apr</month>
            <day>15</day>
            <volume>59</volume>
            <issue>8</issue>
            <fpage>2223</fpage>
            <page-range>2223-30</page-range>
            <pub-id pub-id-type="pmid">10221307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r50">
          <label>50</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lewis</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Drug-induced liver disease.</article-title>
            <source>Med Clin North Am</source>
            <year>2000</year>
            <month>Sep</month>
            <volume>84</volume>
            <issue>5</issue>
            <fpage>1275</fpage>
            <page-range>1275-311, x</page-range>
            <pub-id pub-id-type="pmid">11026929</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r51">
          <label>51</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Koduru</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Carlisle</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Akhter</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Schroder</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Brandes</surname>
                <given-names>RP</given-names>
              </name>
              <name>
                <surname>Ojcius</surname>
                <given-names>DM</given-names>
              </name>
            </person-group>
            <article-title>NADPH oxidase 4 modulates hepatic responses to lipopolysaccharide mediated by Toll-like receptor-4.</article-title>
            <source>Sci Rep</source>
            <year>2017</year>
            <month>Oct</month>
            <day>30</day>
            <volume>7</volume>
            <issue>1</issue>
            <fpage>14346</fpage>
            <pub-id pub-id-type="pmid">29085012</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r52">
          <label>52</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kundur</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Santhakumar</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Bulmer</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Mildly elevated unconjugated bilirubin is associated with reduced platelet activation-related thrombogenesis and inflammation in Gilbert's syndrome.</article-title>
            <source>Platelets</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>28</volume>
            <issue>8</issue>
            <fpage>779</fpage>
            <page-range>779-785</page-range>
            <pub-id pub-id-type="pmid">28300459</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r53">
          <label>53</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lin</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>O'Donnell</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schwaiger</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Cupples</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Lingenhel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hunt</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kronenberg</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study.</article-title>
            <source>Circulation</source>
            <year>2006</year>
            <month>Oct</month>
            <day>03</day>
            <volume>114</volume>
            <issue>14</issue>
            <fpage>1476</fpage>
            <page-range>1476-81</page-range>
            <pub-id pub-id-type="pmid">17000907</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r54">
          <label>54</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van der Veere</surname>
                <given-names>CN</given-names>
              </name>
              <name>
                <surname>Sinaasappel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>McDonagh</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Rosenthal</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Labrune</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Odi&#x000e8;vre</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Fevery</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Otte</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>McClean</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>B&#x000fc;rk</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Masakowski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Sperl</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Mowat</surname>
                <given-names>AP</given-names>
              </name>
              <name>
                <surname>Vergani</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Wilson</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Shepherd</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>PL</given-names>
              </name>
            </person-group>
            <article-title>Current therapy for Crigler-Najjar syndrome type 1: report of a world registry.</article-title>
            <source>Hepatology</source>
            <year>1996</year>
            <month>Aug</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>311</fpage>
            <page-range>311-5</page-range>
            <pub-id pub-id-type="pmid">8690398</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r55">
          <label>55</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Good</surname>
                <given-names>WV</given-names>
              </name>
              <name>
                <surname>Hou</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Visuocortical bilirubin-induced neurological dysfunction.</article-title>
            <source>Semin Fetal Neonatal Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-41</page-range>
            <pub-id pub-id-type="pmid">25577655</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r56">
          <label>56</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Olds</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Oghalai</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Audiologic impairment associated with bilirubin-induced neurologic damage.</article-title>
            <source>Semin Fetal Neonatal Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>42</fpage>
            <page-range>42-46</page-range>
            <pub-id pub-id-type="pmid">25575899</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r57">
          <label>57</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rose</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Vassar</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Movement disorders due to bilirubin toxicity.</article-title>
            <source>Semin Fetal Neonatal Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>20</fpage>
            <page-range>20-25</page-range>
            <pub-id pub-id-type="pmid">25524299</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r58">
          <label>58</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wusthoff</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Loe</surname>
                <given-names>IM</given-names>
              </name>
            </person-group>
            <article-title>Impact of bilirubin-induced neurologic dysfunction on neurodevelopmental outcomes.</article-title>
            <source>Semin Fetal Neonatal Med</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>52</fpage>
            <page-range>52-57</page-range>
            <pub-id pub-id-type="pmid">25585889</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r59">
          <label>59</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Amin</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Saluja</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Saili</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Orlando</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Laroia</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Agarwal</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Chronic Auditory Toxicity in Late Preterm and Term Infants With Significant Hyperbilirubinemia.</article-title>
            <source>Pediatrics</source>
            <year>2017</year>
            <month>Oct</month>
            <volume>140</volume>
            <issue>4</issue>
            <pub-id pub-id-type="pmid">28954873</pub-id>
          </element-citation>
        </ref>
        <ref id="article-23157.r60">
          <label>60</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Newman</surname>
                <given-names>TB</given-names>
              </name>
              <name>
                <surname>Liljestrand</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Jeremy</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Ferriero</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>YW</given-names>
              </name>
              <name>
                <surname>Hudes</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Escobar</surname>
                <given-names>GJ</given-names>
              </name>
              <collab>Jaundice and Infant Feeding Study Team</collab>
            </person-group>
            <article-title>Outcomes among newborns with total serum bilirubin levels of 25 mg per deciliter or more.</article-title>
            <source>N Engl J Med</source>
            <year>2006</year>
            <month>May</month>
            <day>04</day>
            <volume>354</volume>
            <issue>18</issue>
            <fpage>1889</fpage>
            <page-range>1889-900</page-range>
            <pub-id pub-id-type="pmid">16672700</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
